Recipharm

Recipharm AB operates as a pharmaceutical contract development and manufacturing company. Its dosage forms include solid dose, steriles, semi solids, beta-lactams, hormones, dry powder inhalers, granulates, and powders. The company provides pharmaceutical development services, such as formulation development, clinical supplies, analytical development, stability studies, packaging development and selection, and raw material selection; and manufacturing services. It also offers EU gateway release and testing, regulatory, stability studies, and customized services. Recipharm AB was founded in 1995 and is based in Haninge, Sweden. It has manufacturing facilities in Sweden, France, and the United Kingdom.

Company Growth (employees)
Type
Public
HQ
Stockholm, SE
Size (employees)
2,838 (est)+8%
Recipharm is headquartered in Stockholm, SE

Key People at Recipharm

Thomas Eldered

Thomas Eldered

CEO
Sture Nordberg

Sture Nordberg

Vice President of Science & Technology

Recipharm Office Locations

Recipharm has an office in Stockholm
Stockholm, SE (HQ)
Lagervagen 7

Recipharm Metrics

Recipharm Financial Metrics

Recipharm's revenue was reported to be kr3.5 b in FY, 2015 which is a 32% increase from the previous period.

Revenue (FY, 2015)

kr3.5 b

Revenue growth (FY, 2014 - FY, 2015), %

32%

Gross profit (FY, 2015)

kr2.6 b

Gross profit margin (FY, 2015), %

73%

Net income (FY, 2015)

kr215.1 m

EBIT (FY, 2015)

kr274.2 m

EBITDA (FY, 2015)

kr509.8 m

Cash (31-Dec-2015)

kr534.2 m
FY, 2014FY, 2015

Revenue

kr2.7 bkr3.5 b

Revenue growth, %

32%

Cost of goods sold

kr703.9 mkr958.8 m

Gross profit

kr2 bkr2.6 b

Gross profit Margin, %

74%73%

Sales and marketing expense

kr588.7 mkr799.7 m

General and administrative expense

kr888.6 mkr1.2 b

Operating expense total

kr1.5 bkr2 b

Depreciation and amortization

kr127.2 mkr235.6 m

EBITDA

kr399.3 mkr509.8 m

EBITDA margin, %

15%14%

EBIT

kr272.1 mkr274.2 m

EBIT margin, %

10%8%

Interest expense

kr65.4 mkr29 m

Interest income

kr9.3 mkr64.4 m

Pre tax profit

kr216.1 mkr309.6 m

Income tax expense

kr55.9 mkr94.6 m

Net Income

kr160.2 mkr215.1 m
Y, 2014Y, 2015

Cash

kr404.5 mkr534.2 m

Total Assets

kr5.4 bkr5.7 b

Total Debt

kr1.6 bkr1.7 b

Total Liabilities

kr5.4 bkr3 b
FY, 2014FY, 2015

Cash From Operating Activities

kr254.2 mkr428.8 m
Y, 2015

Revenue/Employee

kr7.2 m

Recipharm Revenue Breakdown

Recipharm Company Life

You may also be interested in